0001104659-20-026184.txt : 20200227 0001104659-20-026184.hdr.sgml : 20200227 20200227162030 ACCESSION NUMBER: 0001104659-20-026184 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200226 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200227 DATE AS OF CHANGE: 20200227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMMUNOMEDICS INC CENTRAL INDEX KEY: 0000722830 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 611009366 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-12104 FILM NUMBER: 20662361 BUSINESS ADDRESS: STREET 1: 300 AMERICAN RD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 BUSINESS PHONE: 9736058200 MAIL ADDRESS: STREET 1: 300 AMERICAN ROAD CITY: MORRIS PLAINS STATE: NJ ZIP: 07950 8-K 1 tm2011092-1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2020

IMMUNOMEDICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		000-12104		61-1009366
(State or other jurisdiction of incorporation)		(Commission File Number		(IRS Employer Identification No.)

300 The American Road Morris Plains, New Jersey		07950
(Address of Principal Executive Offices)		(Zip Code)

(973) 605-8200

Registrant’s telephone number, including area code

(Former name or former address if changed since last report,)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.01 par value	IMMU	Nasdaq Stock Market LLC

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Robert Azelby as a Director of the Company

On February 26, 2020, upon recommendation of the Governance and Nominating Committee of the Board of Directors (the “Board”) of Immunomedics, Inc. (the “Company”), the Board appointed Robert Azelby to serve as a director of the Company, effective immediately.

Mr Azelby, age 52, was most recently the President and Chief Executive Officer of Alder BioPharmaceutials, Inc. from June 2018 to November 2019. From November 2015 to May 2018, Mr. Azelby served as Executive Vice President, Chief Commercial Officer of Juno Therapeutics, Inc. From June 2012 to October 2015, Mr. Azelby served as Vice President and General Manager, Oncology at Amgen Inc. From October 2010 to May 2012, he served as Amgen’s Vice President, Amgen Oncology Sales. Prior to that, he served in various positions at Amgen, including periods as Vice President, Commercial Effectiveness Unit and General Manager of Amgen Netherlands. Mr. Azelby currently serves on the board of directors of Clovis Oncology, Inc. Mr. Azelby holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School.

Mr. Azelby contributes important industry, financial and executive-level experience to the Board. In particular, the Board believes Mr. Azelby’s extensive commercial experience in the life sciences industry make him well qualified to serve as a member of the Board.

In connection with his service as non-employee director, Mr Azelby will receive compensation in accordance with the Company’s compensation practices for non-employee directors described in the Company’s definitive proxy statement for the its 2019 annual meeting of stockholders, filed with the United States Securities and Exchange Commission on April 30, 2019, under the caption “Director Compensation.”

There are no family relationships between Mr Azelby and any of the Company’s directors or executive officers and there are no arrangements or understandings between Mr Azelby and any other persons pursuant to which he was selected as a director of the Company. There have been no transactions since the beginning of the Company’s last fiscal year, and there are no currently proposed transactions, in which the Company was or is to be a participant and in which Mr Azelby or any member of his immediate family had or will have any interest, that are required to be reported under Item 404(a) of Regulation S-K.

Item 8.01.

Other Events

On February 27, 2020, the Company issued a press release announcing Mr . Azelby’s appointment to the Board. The full text of the press release is filed as Exhibit 99.1 to the Current Report on Form 8-K.

Item 9.01.

Financial Statements and Exhibits.

Exhibit No.		Exhibit

99.1		Press Release of Immunomedics, Inc., dated February 27, 2020

104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 27, 2020	By:	/s/ Usama Malik
		Name: Usama Malik
		Title: Chief Financial Officer

EX-99.1 2 tm2011092d1_99-1.htm EXHIBIT 99.1

Exhibit 99.1

NEWS RELEASE

IMMUNOMEDICS APPOINTS ROBERT W. AZELBY TO BOARD OF DIRECTORS

Morris Plains, N.J., Feb. 27, 2020 --- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADCs), today announced the appointment of Robert W. Azelby to the Company’s board of directors. Mr. Azelby is a biotech industry veteran with 28 years of biopharmaceutical experience with a large emphasis on commercialization.

“I am excited to join Immunomedics at an inflection point as the Company is preparing for its first potential commercial launch in its history,” said Mr. Azelby. “I believe that sacituzumab govitecan will become a highly impactful and innovative product across hard-to-treat cancers, and I look forward to working closely with the board to establish Immunomedics as a fully-integrated biopharmaceutical company and a leader in the field of ADCs.”

Mr. Azelby was recently the president and chief executive officer, and a member of the board of directors, of Alder BioPharmaceuticals, Inc., which was acquired by H. Lundbeck A/S in October 2019. Previously, Mr. Azelby served as executive vice president, chief commercial officer of Juno Therapeutics, Inc. where he was responsible for the development and implementation of Juno’s CAR-T commercial strategy and helped guide the organization through rapid growth and ultimately to a $9 billion acquisition by Celgene Corporation. Prior to joining Juno, Mr. Azelby spent 15 years at Amgen Inc. building high-performing commercial teams and leading their U.S. Oncology business.

“We are honored to have Bob join our board at a critical point of our evolution into a commercial organization. Bob will also bring his leadership and experience to shape our commercial strategy in other regions of the world, as we strive to bring what we believe is a critical new therapy to people with mTNBC globally,” said Dr. Behzad Aghazadeh, executive chairman of Immunomedics.

Mr. Azelby currently serves on the board of directors of Clovis Oncology, Inc. and he previously served on the board of directors of Cascadian Therapeutics, Inc. Mr. Azelby holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School.

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Immunomedics’ corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates. For additional information on the Company, please visit its website at https://immunomedics.com/. The information on its website does not, however, form a part of this press release.

~ more ~

Cautionary note regarding forward-looking statements

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding expectations for the outcome of our resubmission of our Biologics License Application ("BLA") for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer ("mTNBC") who have received at least two prior therapies for metastatic disease; the United States Food and Drug Administration ("FDA") re-inspection of the Company’s manufacturing facility where we manufacture the monoclonal antibody for further manufacture into our antibody-drug-conjugate candidate sacituzumab govitecan; potential approval and commercial launch of sacituzumab govitecan for that indication and the Company’s development of sacituzumab govitecan for additional indications; clinical trials (including the funding therefor, anticipated patient enrollment, trial outcomes, timing or associated costs); regulatory applications and related timelines, including the filing and approval timelines for BLAs, BLA resubmissions, and BLA supplements; out-licensing arrangements; forecasts of future operating results, potential collaborations, capital raising activities, and the timing for bringing any product candidate to market; our inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to obtain additional capital through strategic collaborations, licensing, convertible debt securities or equity financing in order to continue our research and development programs as well as secure regulatory approval of and market our drug candidates; our dependence upon pharmaceutical and biotechnology collaborations; the levels and timing of payments under our collaborative agreements; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products; our ability to protect our proprietary technologies; patent infringement claims; and risks of new, changing and competitive technologies and regulations in the United States and internationally, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information:

Dr. Chau Cheng

(862) 260-3727

ccheng@immunomedics.com

For Media Inquiries:

Darren Opland, Ph.D.

(646) 627-8387

Darren@lifescipublicrelations.com

###

EX-101.SCH 3 immu-20200226.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 immu-20200226_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 immu-20200226_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2011092d1_99-1img002.jpg GRAPHIC begin 644 tm2011092d1_99-1img002.jpg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ilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://immunomedics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2011092-1_8k.htm immu-20200226.xsd immu-20200226_lab.xml immu-20200226_pre.xml tm2011092d1_99-1.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 8 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2011092-1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm2011092-1_8k.htm" ] }, "labelLink": { "local": [ "immu-20200226_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "immu-20200226_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "immu-20200226.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "immu", "nsuri": "http://immunomedics.com/20200226", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2011092-1_8k.htm", "contextRef": "From2020-02-25to2020-02-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://immunomedics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2011092-1_8k.htm", "contextRef": "From2020-02-25to2020-02-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://immunomedics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } XML 9 R1.htm IDEA: XBRL DOCUMENT

Cover	Feb. 26, 2020
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Feb. 26, 2020
Entity File Number	000-12104
Entity Registrant Name	IMMUNOMEDICS, INC.
Entity Central Index Key	0000722830
Entity Tax Identification Number	61-1009366
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	300 The American Road
Entity Address, City or Town	Morris Plains
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07950
City Area Code	973
Local Phone Number	605-8200
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	IMMU
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 10 tm2011092-1_8k_htm.xml IDEA: XBRL DOCUMENT 0000722830 2020-02-25 2020-02-26 iso4217:USD shares iso4217:USD shares 0000722830 false 8-K 2020-02-26 IMMUNOMEDICS, INC. DE 000-12104 61-1009366 300 The American Road Morris Plains NJ 07950 973 605-8200 false false false false false Common Stock, $0.01 par value IMMU NASDAQ EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 14 0001104659-20-026184-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-026184-xbrl.zip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